 Antibiotics, Antineoplastic
"Antibiotics, Antineoplastic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms.
| Descriptor ID |
D000903
|
| MeSH Number(s) |
D27.505.954.248.106
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibiotics, Antineoplastic".
Below are MeSH descriptors whose meaning is more specific than "Antibiotics, Antineoplastic".
This graph shows the total number of publications written about "Antibiotics, Antineoplastic" by people in UAMS Profiles by year, and whether "Antibiotics, Antineoplastic" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2024 | 0 | 2 | 2 | | 2021 | 1 | 1 | 2 | | 2020 | 1 | 0 | 1 | | 2019 | 0 | 1 | 1 | | 2018 | 3 | 0 | 3 | | 2017 | 2 | 0 | 2 | | 2016 | 2 | 1 | 3 | | 2015 | 6 | 1 | 7 | | 2014 | 1 | 2 | 3 | | 2013 | 1 | 2 | 3 | | 2012 | 2 | 1 | 3 | | 2011 | 1 | 2 | 3 | | 2010 | 1 | 0 | 1 | | 2009 | 1 | 1 | 2 | | 2007 | 0 | 1 | 1 | | 2006 | 1 | 1 | 2 | | 2005 | 1 | 0 | 1 | | 2003 | 3 | 0 | 3 | | 2002 | 0 | 2 | 2 | | 2000 | 1 | 0 | 1 | | 1998 | 1 | 0 | 1 | | 1996 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Antibiotics, Antineoplastic" by people in Profiles over the past ten years.
-
Bashiru M, Rayaan M, Ali N, Jenkins SV, Oyebade A, Rahman MS, Griffin RJ, Oyelere AK, Siraj N. Interrogating the Role of Endocytosis Pathway and Organelle Trafficking for Doxorubicin-Based Combination Ionic Nanomedicines. ACS Appl Bio Mater. 2024 Aug 19; 7(8):5359-5368.
-
Pang L, Cai C, Aggarwal P, Wang D, Vijay V, Bagam P, Blamer J, Matter A, Turner A, Ren L, Papineau K, Srinivasasainagendra V, Tiwari HK, Yang X, Schnackenberg L, Mattes W, Broeckel U. Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs-a proof-of-concept study with doxorubicin. Toxicol Sci. 2024 Jun 26; 200(1):79-94.
-
Desai VG, Vijay V, Han T, Moland CL, Phanavanh B, Lee T, Davis KJ, Muskhelishvili L, Stine KC, Fuscoe JC. Doxorubicin-induced delayed-onset subclinical cardiotoxicity in mice. J Appl Toxicol. 2022 05; 42(5):778-792.
-
Urbaniak A, Reed MR, Fil D, Moorjani A, Heflin S, Antoszczak M, Sulik M, Huczynski A, Kupsik M, Eoff RL, MacNicol MC, Chambers TC, MacNicol AM. Single and double modified salinomycin analogs target stem-like cells in 2D and 3D breast cancer models. Biomed Pharmacother. 2021 Sep; 141:111815.
-
Das KC, Muniyappa H, Kundumani-Sridharan V, Subramani J. Thioredoxin Decreases Anthracycline Cardiotoxicity, But Sensitizes Cancer Cell Apoptosis. Cardiovasc Toxicol. 2021 02; 21(2):142-151.
-
Stolarz AJ, Sarimollaoglu M, Marecki JC, Fletcher TW, Galanzha EI, Rhee SW, Zharov VP, Klimberg VS, Rusch NJ. Doxorubicin Activates Ryanodine Receptors in Rat Lymphatic Muscle Cells to Attenuate Rhythmic Contractions and Lymph Flow. J Pharmacol Exp Ther. 2019 11; 371(2):278-289.
-
Lamture G, Crooks PA, Borrelli MJ. Actinomycin-D and dimethylamino-parthenolide synergism in treating human pancreatic cancer cells. Drug Dev Res. 2018 09; 79(6):287-294.
-
Banerjee S, Oza AM, Birrer MJ, Hamilton EP, Hasan J, Leary A, Moore KN, Mackowiak-Matejczyk B, Pikiel J, Ray-Coquard I, Trask P, Lin K, Schuth E, Vaze A, Choi Y, Marsters JC, Maslyar DJ, Lemahieu V, Wang Y, Humke EW, Liu JF. Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study. Ann Oncol. 2018 04 01; 29(4):917-923.
-
Mack JM, Richter GT, Becton D, Salem O, Hill SEM, Crary SE. Short-term side effects and patient-reported outcomes of bleomycin sclerotherapy in vascular malformations. Pediatr Blood Cancer. 2018 06; 65(6):e27008.
-
Yu LR, Cao Z, Makhoul I, Daniels JR, Klimberg S, Wei JY, Bai JP, Li J, Lathrop JT, Beger RD, Todorova VK. Immune response proteins as predictive biomarkers of doxorubicin-induced cardiotoxicity in breast cancer patients. Exp Biol Med (Maywood). 2018 02; 243(3):248-255.
-
Akolkar G, da Silva Dias D, Ayyappan P, Bagchi AK, Jassal DS, Salemi VMC, Irigoyen MC, De Angelis K, Singal PK. Vitamin C mitigates oxidative/nitrosative stress and inflammation in doxorubicin-induced cardiomyopathy. Am J Physiol Heart Circ Physiol. 2017 Oct 01; 313(4):H795-H809.
-
Todorova VK, Makhoul I, Dhakal I, Wei J, Stone A, Carter W, Owen A, Klimberg VS. Polymorphic Variations Associated With Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients. Oncol Res. 2017 Sep 21; 25(8):1223-1229.
-
Akolkar G, Bagchi AK, Ayyappan P, Jassal DS, Singal PK. Doxorubicin-induced nitrosative stress is mitigated by vitamin C via the modulation of nitric oxide synthases. Am J Physiol Cell Physiol. 2017 Apr 01; 312(4):C418-C427.
-
Hao L, Mahmoud F. Image Diagnosis: A Striking Bleomycin-Induced Skin Toxicity: Flagellate Hyperpigmentation. Perm J. 2017; 21:16-001.
-
Todorova VK, Makhoul I, Siegel ER, Wei J, Stone A, Carter W, Beggs ML, Owen A, Klimberg VS. Biomarkers for Presymptomatic Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients. PLoS One. 2016; 11(8):e0160224.
-
Schnackenberg LK, Pence L, Vijay V, Moland CL, George N, Cao Z, Yu LR, Fuscoe JC, Beger RD, Desai VG. Early metabolomics changes in heart and plasma during chronic doxorubicin treatment in B6C3F1 mice. J Appl Toxicol. 2016 11; 36(11):1486-95.
-
Samanta D. Acneiform Lesion: Importance of Detailed Skin Examination. Indian J Pediatr. 2016 May; 83(5):485-6.
-
Zhang W, Deng J, Sunkara M, Morris AJ, Wang C, St Clair D, Vore M. Loss of multidrug resistance-associated protein 1 potentiates chronic doxorubicin-induced cardiac dysfunction in mice. J Pharmacol Exp Ther. 2015 Nov; 355(2):280-7.
-
Deng J, Coy D, Zhang W, Sunkara M, Morris AJ, Wang C, Chaiswing L, St Clair D, Vore M, Jungsuwadee P. Elevated glutathione is not sufficient to protect against doxorubicin-induced nuclear damage in heart in multidrug resistance-associated protein 1 (Mrp1/Abcc1) null mice. J Pharmacol Exp Ther. 2015 Nov; 355(2):272-9.
-
Yeh ET, Vejpongsa P. Subclinical Cardiotoxicity Associated With?Cancer Therapy: Early Detection and Future Directions. J Am Coll Cardiol. 2015 Jun 16; 65(23):2523-5.
-
Singh P, Sharma R, McElhanon K, Allen CD, Megyesi JK, Bene? H, Singh SP. Sulforaphane protects the heart from doxorubicin-induced toxicity. Free Radic Biol Med. 2015 Sep; 86:90-101.
-
Kushnir CL, Angarita AM, Havrilesky LJ, Thompson S, Spahlinger D, Sinno AK, Tanner EJ, Secord AA, Roche KL, Stone RL, Fader AN. Selective cardiac surveillance in patients with gynecologic cancer undergoing treatment with pegylated liposomal doxorubicin (PLD). Gynecol Oncol. 2015 Jun; 137(3):503-7.
-
Mohamed RH, Karam RA, Hagrass HA, Amer MG, Abd El-Haleem MR. Anti-apoptotic effect of spermatogonial stem cells on doxorubicin-induced testicular toxicity in rats. Gene. 2015 Apr 25; 561(1):107-14.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|